Modality
mAb
MOA
Anti-Aβ
Target
TROP-2
Pathway
Apoptosis
Heart FailureT2D
Development Pipeline
Preclinical
~Jul 2021
→ ~Oct 2022
Phase 1
Jan 2023
→ Aug 2029
Phase 1Current
NCT05630257
1,964 pts·T2D
2023-05→2026-01·Not yet recruiting
NCT03283437
2,691 pts·T2D
2023-01→2029-08·Terminated
4,655 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-023mo agoPh2 Data· T2D
2029-08-083.4y awayPh2 Data· T2D
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1/2
Termina…
P1/2
Not yet…
Catalysts
Ph2 Data
2026-01-02 · 3mo ago
T2D
Ph2 Data
2029-08-08 · 3.4y away
T2D
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05630257 | Phase 1/2 | T2D | Not yet recr... | 1964 | Mayo |
| NCT03283437 | Phase 1/2 | T2D | Terminated | 2691 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| ILM-4317 | Illumina | NDA/BLA | TROP-2 |